COEP.NASDAQCoeptis Therapeutics Holdings, INC
10-Q: Coeptis Therapeutics Holdings Reports Second Quarter 2024 Financial Results
Sentiment:
Quarterly Report
Coeptis Therapeutics Holdings reported a net loss of $6.04 million for the six months ended June 30, 2024, while continuing to focus on product development and strategic partnerships.
Capital raiseThe company completed an initial closing of a Series A preferred stock offering, raising $4.3 million.A second closing of the Series A preferred stock offering raised an additional $1.3 million.The company is dependent on raising additional capital through sales of equity or debt securities to pursue its business plans and sustain operations.
Worse than expectedThe company reported a net loss of $6.04 million for the six months ended June 30, 2024, which is worse than the prior year period.The company has an accumulated deficit of $93.39 million as of June 30, 2024, indicating a continued trend of losses.
Summary
- Coeptis Therapeutics Holdings reported a net loss of $3.04 million for the three months ended June 30, 2024, and a net loss of $6.04 million for the six months ended June 30, 2024.
- The company's operating expenses were $2.83 million for the quarter and $5.75 million for the six-month period.
- The company had cash and cash equivalents of $1.56 million as of June 30, 2024, compared to $1.47 million at the end of 2023.
- The company is focused on developing cell therapy technologies for cancer and other diseases.
- Coeptis is exploring partnership opportunities with companies that have novel therapies or technologies to improve drug delivery.
- The company is developing CD38-GEAR-NK and CD38-Diagnostic product candidates in collaboration with Vy-Gen Bio, Inc.
- Coeptis has also licensed a stem cell expansion platform from Deverra Therapeutics, Inc.
- The company completed a Series A preferred stock offering, raising $4.3 million in the initial closing and an additional $1.3 million in a second closing.
- The company has an accumulated deficit of $93.39 million as of June 30, 2024.
Sentiment
Score: 4
Explanation: The document presents a mixed picture. While the company has made progress in securing funding and advancing its product pipeline, the significant net losses, accumulated deficit, and ineffective disclosure controls raise concerns about its financial stability and operational efficiency. The company's future success is highly dependent on its ability to secure additional funding and achieve commercial milestones.
Positives
- The company successfully raised $4.3 million in the initial closing of a Series A preferred stock offering and an additional $1.3 million in a second closing.
- The company is actively pursuing strategic partnerships to expand its product portfolio.
- The company is advancing the development of its CD38-GEAR-NK and CD38-Diagnostic product candidates.
- The company has secured an exclusive license for a stem cell expansion platform from Deverra Therapeutics, Inc.
Negatives
- The company reported a net loss of $6.04 million for the six months ended June 30, 2024.
- The company has an accumulated deficit of $93.39 million as of June 30, 2024.
- The company's disclosure controls and procedures were not operating effectively as of June 30, 2024.
- The company has limited financial resources and is dependent on raising additional capital.
Risks
- The company's ability to continue as a going concern is dependent on obtaining sufficient financing or establishing a profitable business.
- The company's disclosure controls and procedures were not operating effectively, indicating potential issues with financial reporting.
- The company has a history of losses and may not achieve profitability.
- The company is dependent on strategic partnerships and may not be able to secure favorable terms.
- The company's product development efforts are subject to regulatory risks and may not be successful.
- The company's financial results are subject to market risks and fluctuations.
Future Outlook
The company expects to continue focusing on product development, strategic partnerships, and raising capital to support its operations. Management does not expect the Company to generate any significant revenue for at least the next two years.
Management Comments
- Management believes that additional financing as necessary will result in improved operations and cash flow.
- Management does not expect the Company to generate any significant revenue for at least the next two years, during which time drug development will continue toward the goal of commercializing, through a partnership or otherwise, one or more of the Company's target products or technologies.
Industry Context
The company is operating in the competitive biopharmaceutical industry, focusing on cell therapy technologies for cancer and other diseases. The company is actively seeking strategic partnerships to enhance its product development and commercialization efforts. The company's focus on innovative technologies and therapies aligns with the broader industry trend of developing novel treatments for unmet medical needs.
Comparison to Industry Standards
- The company's financial performance, with significant net losses and an accumulated deficit, is not uncommon for early-stage biopharmaceutical companies that are heavily investing in research and development.
- Compared to companies like Juno Therapeutics (acquired by Celgene) or Kite Pharma (acquired by Gilead), which also focused on cell therapies, Coeptis is at a much earlier stage of development and has not yet achieved significant revenue or commercial success.
- The company's reliance on strategic partnerships and licensing agreements is a common strategy in the biotech industry, similar to companies like Adaptimmune or bluebird bio, which also collaborate with larger pharmaceutical companies to advance their therapies.
- The company's focus on CD38-related cancers and NK cell therapies is aligned with current trends in immuno-oncology, where these approaches are gaining increasing attention and investment.
- The company's financial metrics, such as cash burn and operating expenses, are typical for companies in the pre-revenue stage of development, but the company will need to demonstrate progress in clinical trials and commercialization to attract further investment.
Related Party Transactions
- In September 2023, the Company entered into a transaction with AG Bio Life Capital I LP (AG), a Delaware limited partnership, where an employee of the Company is the general partner.
Stakeholder Impact
- Shareholders are impacted by the company's net losses and accumulated deficit, which may affect the value of their investment.
- Employees are impacted by the company's financial condition, which may affect job security and compensation.
- Customers and partners are impacted by the company's ability to develop and commercialize its products and technologies.
- Creditors are impacted by the company's debt obligations and ability to repay its loans.
Next Steps
- The company will continue to focus on product development and strategic partnerships.
- The company will continue to seek additional financing through equity or debt securities.
- The company will work to remediate the material weaknesses in its internal control over financial reporting.
Key Dates
| Date | Description |
|---|---|
| 2017-07-12 | Coeptis Pharmaceuticals, LLC was formed. |
| 2018-11-27 | Bull Horn Holdings Corp. was originally incorporated in the British Virgin Islands. |
| 2020-07-08 | The company received an EIDL loan of $150,000 from the SBA. |
| 2021-02-12 | Vinings Holdings, Inc. merged with Coeptis Pharmaceuticals, Inc. |
| 2021-05-28 | Coeptis Therapeutics, Inc. issued a warrant to a third party for professional services. |
| 2021-07-30 | Coeptis Therapeutics, Inc. issued a warrant to a third party for professional services. |
| 2021-08-15 | The company entered into amendments to the CD38 Agreements with Vy-Gen Bio, Inc. |
| 2021-09-22 | Coeptis Therapeutics, Inc. issued a warrant to Purple Biotech. |
| 2021-12-20 | Coeptis Therapeutics, Inc. issued a warrant to a third party for services. |
| 2022-01-28 | Coeptis Therapeutics, Inc. issued warrants to multiple third parties. |
| 2022-03-30 | Coeptis Therapeutics, Inc. issued a warrant to a third party in conjunction with an investment. |
| 2022-04-29 | The company entered into an exclusive option agreement with University of Pittsburgh. |
| 2022-08-31 | The company entered into an exclusive license agreement with the University of Pittsburgh for CAR T technology. |
| 2022-10-27 | Bull Horn Holdings Corp. domesticated from the British Virgin Islands to the State of Delaware. |
| 2022-10-28 | Bull Horn Holdings Corp. merged with Coeptis Therapeutics, Inc. and changed its name to Coeptis Therapeutics Holdings, Inc. |
| 2023-01-03 | Coeptis Therapeutics, Inc. issued warrants to third parties for professional services. |
| 2023-06-16 | The company completed a public offering issuing common stock and warrants. |
| 2023-07-14 | The company and Purple Biotech executed an amendment to revise the notes payment schedule. |
| 2023-08-16 | The company entered into an exclusive licensing arrangement with Deverra Therapeutics Inc. |
| 2023-09-28 | The company received FDA's response to its 513(g) request for information submission pertaining to the classification of the CD38-Diagnostic. |
| 2023-10-26 | The company completed a private placement of common stock and warrants. |
| 2023-12-28 | The company granted pre-funded warrants. |
| 2024-01-03 | The company entered into an unsecured note agreement with a third party. |
| 2024-01-30 | The company signed a fourth lease extension for office space. |
| 2024-02-08 | The company granted pre-funded warrants. |
| 2024-04-17 | The company entered into an unsecured note agreement with a related party. |
| 2024-06-14 | The company performed an initial closing and raised $4.3 million in a sale of Series A preferred stock. |
| 2024-06-19 | The company and Purple Biotech executed another amendment to extend the maturity date of the convertible note. |
| 2024-06-25 | The company and an unrelated third party signed an amendment to a convertible note. |
| 2024-07-31 | The company performed a second closing as part of its series A preferred stock offering and raised $1.3 million. |
| 2024-08-12 | The company satisfied $5.7 million of subscription receivables in the form of shares of common stock in two privately held companies. |
Keywords
cell therapy, cancer, biopharmaceutical, CD38-GEAR-NK, CD38-Diagnostic, stem cell, licensing, preferred stock, clinical trials, warrants
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.